



**PROFICIENCY TESTING REPORT**  
**ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME**  
 NABL accredited program as per ISO/IEC 17043:2010 standard  
 Organized By Department of Hematology, AIIMS, New Delhi-110029



*Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens*

EQAP CODE No. : 5822

Distribution No.: 160-0

Month/Year: July/2023

Instrument ID: Mindray BC 3600 (TB89002330)

Name & Contact No. of PT Co-ordinator: Dr. Manoranjan Mahapatra ( Prof. & Head), Hematology, AIIMS, Delhi,  
Tel: 9013085730 , E-Mail : accuracy2000@gmail.com

Date of issue &amp; status of the report: 19-09-2023[Final].

### CBC and Retic Assessment

| Test Parameters           | S.No. | Among Lab (Accuracy Testing) |               |                             |   |                                |         | Within Lab (Precision Testing)  |   |                                |         |
|---------------------------|-------|------------------------------|---------------|-----------------------------|---|--------------------------------|---------|---------------------------------|---|--------------------------------|---------|
|                           |       | Your Result 1                | Your Result 2 | Your Results Sum of 2 Value | Consensus result sum of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score | Yours Results Diff. of 2 Values | Consensus Result Diff. of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score |
| WBC x10 <sup>3</sup> /µl  | 1     | 3.7                          | 3.7           | 7.4                         | 6.86  | 0.043                          | 0.62    | 0                               | 0.08  | 0.006                          | -1.20   |
| RBC x10 <sup>6</sup> /µl  | 1     | 5.78                         | 5.59          | 11.37                       | 9.52  | 0.016                          | 5.96    | 0.19                            | 0.04  | 0.004                          | 2.79    |
| Hb g/dl                   | 1     | 11.6                         | 11.6          | 23.2                        | 25.3  | 0.036                          | -2.58   | 0                               | 0.1   | 0.011                          | -0.67   |
| HCT%                      | 1     | 48.1                         | 46.5          | 94.6                        | 80.7  | 0.256                          | 2.59    | 1.6                             | 0.4   | 0.045                          | 2.02    |
| MCV-fl                    | 1     | 83.3                         | 83.1          | 166.4                       | 169.25  | 0.451                          | -0.29   | 0.2                             | 0.3   | 0.030                          | -0.22   |
| MCH-Pg                    | 1     | 20.8                         | 20.1          | 40.9                        | 53  | 0.104                          | -6.09   | 0.7                             | 0.2   | 0.018                          | 2.25    |
| MCHC-g/dl                 | 1     | 25                           | 24.1          | 49.1                        | 63.1  | 0.231                          | -3.02   | 0.9                             | 0.3   | 0.027                          | 1.70    |
| Plt. x10 <sup>3</sup> /µl | 1     | 193                          | 186           | 379                         | 316.5   | 2.317                          | 1.22    | 7                               | 7   | 0.578                          | 0.00    |
| Retic %                   | 2     | 0.02                         | 0.01          | 0.03                        | 1.58  | 0.054                          | -1.07   | 0.01                            | 0.2   | 0.014                          | -0.79   |

### P.S . Assesment

| YOUR REPORT    |   | CONSENSUS REPORT   |
|----------------|---|--|
| DLC%           | 3 | Nrbcs=1 , Poly=46 L=04, E=02, Mono/Promono= , B1=18 P.M.=08, Mye=09, Meta=10, Other=   |
| RBC Morphology | 3 | Poly: 37 - 52, Myelo: 15 - 27, Meta: 9- 17, Promyelo: 2-8, Lympho: 2- 5, Blast: 1-4, Eosino: 1-3, Mono: 1-2, nRBC/ Baso: 0-5 |
| Diagnosis      | 3 | Chronic Myelocytic Leukaemia   |
|                |   | Chronic Myeloid Leukemia (Chronic Phase)   |

**COMBINED DATA VALUES OF TOTAL PARTICIPANTS**

| Test parameters                | S.No. | Total participants covered in the current dist. 160--O | Total No. responded | % of Labs with Z Score 0-2                                      |            | % of Labs with Z Score 2-3 |            | % of Labs with Z Score >3 |            |
|--------------------------------|-------|--|---------------------|---|------------|----------------------------|------------|---------------------------|------------|
|                                |       |  |                     | Among labs  | Within lab | Among labs                 | Within lab | Among labs                | Within lab |
| <b>WBC x10<sup>3</sup>/µl</b>  | 1     | 199  | 198                 | 86.36   | 93.43      | 3.54                       | 1.01       | 10.1                      | 5.56       |
| <b>RBC x10<sup>6</sup>/µl</b>  | 1     | 199  | 199                 | 87.44   | 86.93      | 5.53                       | 5.53       | 7.03                      | 7.54       |
| <b>Hb g/dl</b>                 | 1     | 199  | 199                 | 86.93   | 82.91      | 6.53                       | 5.53       | 6.54                      | 11.56      |
| <b>HCT%</b>                    | 1     | 199  | 198                 | 92.93   | 90.4       | 2.53                       | 3.03       | 4.54                      | 6.57       |
| <b>MCV-fl</b>                  | 1     | 199  | 198                 | 92.42   | 87.88      | 6.57                       | 4.04       | 1.01                      | 8.08       |
| <b>MCH-Pg</b>                  | 1     | 199  | 198                 | 83.33   | 92.93      | 9.09                       | 1.01       | 7.58                      | 6.06       |
| <b>MCHC-g/dl</b>               | 1     | 199  | 198                 | 90.91   | 85.86      | 5.56                       | 5.05       | 3.53                      | 9.09       |
| <b>Plt. x10<sup>3</sup>/µl</b> | 1     | 199  | 198                 | 89.39   | 92.93      | 6.06                       | 3.54       | 4.55                      | 3.53       |
| <b>ReticCount%</b>             | 2     | 199  | 151                 | 85.43   | 92.72      | 7.28                       | 9.93       | 7.29                      | -2.65      |
| <b>PS Assessment</b>           | 3     | 199  | 163                 | Satisfactory :98.5%, Borderline Sat. :0%, Unsatisfactory :1.50% |            |                            |            |                           |            |

**\*Comments:**

1). **Among Lab (EQA) : CBC result for RBC, MCH & MCHC unacceptable, please check calibration/human error. Remaining results acceptable.**

2). **Within Lab (IQA) : Precision acceptable.**

**Note-1: EQA** (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

**IQA** ( Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

**Note-2:** Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

**Note-3:** Z score 0 to ±2: Acceptable, Z score ±2 to ±3 :Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2015 standard]

**Note-4:** Z score value between "0 to ±2" are texted in green colour. Z score value between "±2 to ±3" are texted in orange colour. Z score value > ±3 are texted in red colour.

**Note-5:** Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3\*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ( $\bar{x}-\bar{y}$ ) should be smaller than the check value (0.3\*SDPA).

**Note-6:** ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

**Note-7:** Participants are free to use methods/analyzer of their own choice.

**Note-8:** Proficiency testing (PT ) samples are sent quarterly to each participant.

**Note-9:** All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website [www.ishtmaiimseqap.com](http://www.ishtmaiimseqap.com).

**Note 10:** Reports are kept confidential.

Report authorized by,



Dr. Manoranjan Mahapatra ( Prof. & Head)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----